Callio Therapeutics

Callio Therapeutics is a biotechnology company headquartered in Seattle and Singapore, dedicated to advancing cancer therapy through the development of next-generation, multi-payload antibody drug conjugates (ADCs). The company focuses on creating ADCs with differentiated payload and linker technologies, enabling the targeted delivery of drug combinations directly to tumor cells. This approach aims to maximize therapeutic benefits for cancer patients. Callio's lead program involves a dual payload HER2 targeted ADC, with plans to achieve clinical proof of concept using funds from a $187 million Series A financing round. The company serves the oncology market, targeting healthcare providers and institutions involved in cancer treatment. Callio's business model revolves around developing and commercializing its ADC platform, generating revenue through partnerships, licensing agreements, and potential acquisitions. The company is led by Adam Simpson, an experienced executive with a background in life sciences and company creation.

Keywords: biotechnology, antibody drug conjugates, cancer therapy, HER2, oncology, targeted delivery, tumor cells, clinical proof, financing, Seattle